Androxal Enclomiphene 25mg 100pcs Oral Steroids Tablets

Description

Enclomiphene Androxal Oral SERM Testosterone Research

About This Compound

Androxal (Enclomiphene Citrate) is the purified trans-isomer of clomiphene citrate, specifically isolated to provide potent anti-estrogenic signaling without the mixed-agonist properties of the cis-isomer (Zuclomiphene). This signaling molecule serves as a premier research tool for investigating the restoration of the Hypothalamic-Pituitary-Testicular Axis (HPTA) and the stimulation of endogenous testosterone production. [Enclomiphene activates the HPTA]. By selectively antagonizing estrogen receptors at the pituitary gland, it provides a high-fidelity model for evaluating hormonal homeostasis without the side effects associated with racemic clomiphene blends.

Molecular Data

• CAS Number: 15690-57-0 (Base) / 7599-79-3 (Citrate)
• Molecular Formula: C26H28ClNO
• Molecular Weight: 405.96 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Mechanism Overview

The biochemical activity of Enclomiphene is defined by its ability to competitively bind to estrogen receptors in the anterior pituitary gland. The primary mechanism involves the molecule occupies these receptors, blocking the negative feedback signaling of circulating estrogens. This defines the first semantic triple: [Enclomiphene antagonizes pituitary estrogen receptors]. Following this, the perceived lack of estrogen triggers the hypothalamus to increase the pulsatile release of Gonadotropin-Releasing Hormone (GnRH), which in turn stimulates the pituitary to secrete Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This establishes the second triple: [Estrogen receptor blockade stimulates LH/FSH release]. Finally, the elevated LH signaling at the Leydig cells induces a significant increase in the synthesis and secretion of endogenous testosterone. This forms the third triple: [Increased LH elevations stimulate testosterone production]. Quantitatively, Enclomiphene demonstrates a systemic half-life of approximately 10.5 hours. Unlike Zuclomiphene, which remains in the system for weeks and exhibits estrogenic activity, Enclomiphene is rapidly cleared, allowing for precise control over the research environment.

Experimental Outcomes

• Restoration of Endogenous Testosterone: Users in research models report substantial increases in total and free testosterone levels following HPTA suppression.
• Optimized Spermatogenesis: Controlled trials show improved sperm count and motility markers through the elevation of FSH signaling.
• Preservation of Libido: Based on community feedback, research models show maintained sexual function compared to aromatase inhibitors, likely due to stable estrogen receptor signaling in peripheral tissues.
• Reduced Estrogenic Side Effects: Cumulative findings indicate a significant reduction in mood swings and visual disturbances typically associated with racemic Clomid.
• Maintained Bone Density: Research models have observed that while it blocks pituitary feedback, it maintains enough systemic estrogenic signaling to support skeletal health.

In Brief:
Androxal Enclomiphene represents a premier research tool for investigating the targeted stimulation of the HPTA and the molecular control of endogenous androgen production.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.